EIP is delighted to announce a NEW free-to-access webinar on Spotting the Signs of Mucopolysaccharidosis (MPS)
	MPS Case Studies Practical Examples of an Effective Identification and Referral Process
	6 April 2022
	The webinar is now organised. Register to access the video.
	Can't attend the live event? By registering, you will receive a link to the on-demand version after the session concludes.
	COURSE DESCRIPTION
	Misdiagnosis of Mucopolysaccharidosis (MPS) results in late diagnosis and the late start of treatment, which has significant consequences on long-term outcomes. This gap usually results in confusing symptoms with other conditions, most notably trying to address symptoms directly and therefore delaying actual diagnosis and treatment, or referring the patient to the wrong pediatric specialties causing further delays in the condition’s management chain.
	Language: English ● Duration: 30 minutes followed by questions from the audience
	Presenter: Christina Lampe, Director of the Centre for Rare Diseases of the Department of Child Neurology, Epileptology and Social Medicine, Center for Paediatric and Adolescent Medicine, University Hospital of Gießen, Germany
	TARGET AUDIENCE
	This educational activity is designed for an international audience of General Pediatricians, General Practitioners, Pediatric Endocrinologists, Pediatric Rheumatologists and other physicians and healthcare professionals with an interest in Metabolic Diseases.
	LEARNING OBJECTIVES
	✓ Reviewing the main red flags, signs and symptoms, the basis of diagnostics and when to refer if you suspect MPS
	✓ Better understand how the suspect and confirm MPS patients in your everyday practice
	✓ Increase your awareness about the main presenting signs of mucopolysaccharidoses
	✓ Exploring the clues on when suspect MPS based on the symptoms and family history
	✓ Reviewing how to best follow up with patients - what are the immediate next steps
	Click below to start your free registration

The Spot the Early Signs program aims to fight under-diagnosed or late-diagnosed conditions for which treatments are available and where early detection and early treatment could make a significant difference in the condition's development, the quality of life and the survival of patients.